Clinical Trial Update: Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season [Phase 2]

View source ↗

Summary

A Phase 2 randomized crossover trial evaluated the safety and efficacy of three oral doses of BI 671800 versus fluticasone propionate and montelukast in patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Seasonal Allergic Rhinitis

Drugs mentioned

• BI 671800
• Fluticasone propionate (Fluticasone propionate)
• Montelukast (Montelukast)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Rhinitis, Allergic, Seasonal, Asthma | Phase 2 | Status: COMPLETED